<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076752</url>
  </required_header>
  <id_info>
    <org_study_id>040095</org_study_id>
    <secondary_id>04-C-0095</secondary_id>
    <nct_id>NCT00076752</nct_id>
    <nct_alias>NCT00726518</nct_alias>
  </id_info>
  <brief_title>Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus</brief_title>
  <official_title>A Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine a new approach to treating patients with severe systemic lupus
      erythematosus (SLE) that involves collecting stem cells (cells produced by the bone marrow
      that develop into blood cells) from the patient, completely shutting down the patient's
      immune system, and then giving back the patient's stem cells. SLE is a chronic, inflammatory
      disorder of the immune system that can affect many organs. It is called an autoimmune disease
      because the patient's lymphocytes (white blood cells that normally protect against invading
      organisms), go out of control and attack the body's own tissues.

      Patients between 15 and 40 years of age with severe SLE affecting a major organ that is
      resistant to standard treatment may be eligible for this study. Candidates are screened with
      a medical history and physical examination, blood and urine tests, skin tuberculin test, and
      radiology studies to evaluate the extent of disease. They have endocrinology, nutrition,
      dental, and social work consultations, ultrasound or MUGA (multi-gated acquisition scan) scan
      heart imaging, electrocardiogram and lung function tests, bone marrow biopsy, and lymph node
      aspirate. Depending on which organs are affected, patients may have additional tests, such as
      lumbar puncture (spinal tap), kidney or lung biopsy, MRI (magnetic resonance imaging) of the
      brain and spinal cord, and PET (positron emission tomography) scan. They also complete
      quality of life questionnaires and have disability functional testing and neurocognitive
      (thinking) assessments.

      Participants have a central venous line (plastic tube) inserted into a neck or chest vein for
      administering stem cells and medicines and for drawing blood. They undergo seven apheresis
      procedures during the course of the study to collect stem cells for transplant and for
      research. For apheresis, whole blood is collected through a needle in an arm vein and
      directed to a cell-separating machine where the white cells are extracted and the rest of the
      blood is returned to the patient through the same needle.

      Patients are primed with three medications (methylprednisolone, rituximab, and
      cyclophosphamide) through the central line to help control the disease. In addition, a
      medication called G-CSF (growth colony stimulating factor) is injected under the skin for
      several days to boost production of stem cells. After enough stem cells have been collected
      for transplantation (infusion through the central line), patients are admitted to the
      hospital for an 8-day conditioning regimen followed by transplantation. The conditioning
      treatment consists of rituximab, fludarabine, and cyclophosphamide to eliminate all the white
      blood cells from the blood and bone marrow. The stem cells are then infused and the patient
      is closely monitored by a team of physicians and nurses. When the stem cells have engrafted,
      the bone marrow has recovered, and the patient feels well enough - usually 2 to 3 weeks after
      transplant - the patient is discharged from the hospital. Prednisone tapering begins as soon
      as feasibly possible, but no later then 28 days after transplant.

      Patients return to the National Institutes of Health (NIH) Clinical Center for frequent
      follow-up visits during the first 2 to 3 months following transplant. The time between visits
      is then extended to once every 3 months the first year, then every 6 months the second year,
      and then at least yearly for 5 years after the transplant. These visits include a physical
      examination, blood and urine tests, lumbar puncture (if there is central nervous system
      involvement), other appropriate biopsies and tests as needed to monitor the patient's health,
      short apheresis procedures to collect blood for research purposes, and quality of life
      questionnaires. Some select procedures will be optional. Bone marrow biopsies and lymph node
      aspirates are done at beginning and at 6, 12, and 24 months after transplant. PET scans are
      done at 1, 6, 12, and 24 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can involve
           almost any organ and can range in severity from mild to life-threatening. In spite of
           significant improvements in survival of SLE patients over last 20 years, a small but
           significant portion of patients still develop progressive therapy-refractory disease
           that impairs organ function and overall survival.

        -  Since 1996, more than 500 patients have been treated worldwide in pilot trials of
           autologous hematopoietic stem cell transplantation (autoHSCT) for autoimmune diseases,
           including about 80 patients with SLE.

        -  The rationale for autoHSCT in autoimmune disease is to ablate autoreactive immune
           effectors and allow reconstitution of a new self-tolerant immune system from the

      hematopoietic stem cell. Studies have demonstrated acceptable safety and promising short term
      efficacy of high-dose cyclophosphamide-based (200 mg/kg) autoHSCT for about 60% of patients
      with advanced refractory SLE and reacquisition of sensitivity to conventional drugs have been
      demonstrated in many cases. However, these trials were designed to address the primary
      endpoint of safety and were inadequate for assessing the disease response.

      -Numerous questions about the true efficacy of autoHSCT, optimal transplant regimen, patient
      selection and mechanisms of action remain unaddressed.

      Objectives:

        -  The primary objective is to assess the rate of continuous relapse-free complete clinical
           responses at 24 months post-transplant, with statistical power of 84% to detect, if
           greater than 70 percent of patients meet the primary endpoint.

        -  The long-term goal of this research is to develop a basis for future transplant
           protocols that would incorporate new cellular or other immunotherapeutic interventions
           to further improve results of transplants with the ultimate goal to cure SLE.

      Eligibility:

      -Subjects age 15-40 years who fulfill at least 4 of the 11 criteria for SLE as defined by the

      American College of Rheumatology

      -Have severe and active lupus, refractory to immunosuppressive therapy. Included are subjects
      with nephritis, central nervous system (CNS) lupus, pulmonary lupus or hematologic disease

      Design:

        -  Fourteen patients with active and standard dose cyclophosphamide-resistant SLE will be
           enrolled on this phase II pilot study.

        -  Study design is intended to improve the efficacy of autoHSCT. A lymphoablative
           conditioning regimen (rituximab, fludarabine and cyclophosphamide) is explored for the
           first time in autoimmune disease.

        -  The treatment schedule consists of two parts; the priming regimen prior to stem cell
           mobilization and collection, and the conditioning regimen with transplant.

        -  In contrast to other studies, this study has precisely defined eligibility and disease
           response criteria with strict schema of tapering immunosuppression that should allow
           accurate interpretation of the treatment results.

        -  The study includes a carefully chosen battery of laboratory research studies designed to
           investigate SLE biology and mechanisms of post-transplant responses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 30, 2004</start_date>
  <completion_date type="Actual">October 15, 2013</completion_date>
  <primary_completion_date type="Actual">October 15, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free Complete Clinical Response</measure>
    <time_frame>60 months</time_frame>
    <description>Complete clinical response is defined as complete clinical response in the target organ and no clinical signs of active lupus as determined by a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of ≤3; prednisone ≤10mg/day at 6 months and ≤5mg/day at 12 months or later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>18 months</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Nuclear Antibody</measure>
    <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
    <description>Anti-Nuclear antibody is a well accepted biological clinical laboratory marker of systemic lupus. Range of normal values is 0-0.9 EU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extractable Nuclear Antigen (ENA)</measure>
    <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
    <description>Extractable nuclear antigen is a well accepted biological clinical laboratory marker of systemic lupus. Range of normal values is 0-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Double Stranded Deoxyribonucleic Acid (DNA) Antibody</measure>
    <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
    <description>Anti-Double stranded deoxyribonucleic acid antibody is a well accepted biological clinical laboratory marker especially specific for systemic lupus. Range of normal values is 0-24 IU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Smith-Ribonuclear Protein Antibody</measure>
    <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months and 2 years.</time_frame>
    <description>Anti-Smith-Ribonuclear protein antibody is a well accepted biological clinical laboratory marker of systemic lupus.Range of normal values is 0-19 EU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cells</measure>
    <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
    <description>The white blood cell test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 3.4-9.6 K/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Neutrophil Count</measure>
    <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
    <description>The absolute neutrophil count test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 1.29-7.5 K/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Lymphocyte Count</measure>
    <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
    <description>The absolute lymphocyte count test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 0.45-4.9 K/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Count</measure>
    <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
    <description>The platelet count test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 162-380 K/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cluster of Differentiation 3 (CD3) + Cells</measure>
    <time_frame>Day 0, 1 month, 3 months, 6 months, 1 year and 2 years.</time_frame>
    <description>The CD3+Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 650-2108 uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cluster of Differentiation 4 (CD4) + Cells</measure>
    <time_frame>Day 0, 1 month, 3 months, 6 months, 1 year and 2 years.</time_frame>
    <description>The CD4 + Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 358-1259 uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cluster of Differentiation 8 (CD8) + Cells</measure>
    <time_frame>Day 0, 1 month, 3 months, 6 months, 1 year and 2 years.</time_frame>
    <description>The CD8 + Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 194-836 u/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cluster of Differentiation 19 (CD19) + Cells</measure>
    <time_frame>Day 0, 1 month, 3 months, 6 months, 1 year and 2 years.</time_frame>
    <description>The CD19 + Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 47-409 u/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natural Killer Cells</measure>
    <time_frame>Day 0, 1 month, 3 months, 6 months, 1 year and 2 years.</time_frame>
    <description>The natural killer cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 87-505 uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)</measure>
    <time_frame>Day -7, day 0, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
    <description>The SLEDAI activity index test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Complete clinical response is defined as complete clinical response in the target organ and no clinical signs of active lupus as determined by a SLEDAI score of ≤3; partial response is at least 50% improvement in general disease activity as measured by SLEDAI. Remission is a SLEDAI score &lt;3 and prednisone &lt;10mg/day. 6+ indicates active disease requiring therapy. A score of 0 indicates a better outcome and a score greater then 6+ indicates a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Conditioning and transplant regimen: 30 mg/m^2 day intravenous infusion over 30 minutes daily, 4 days (transplant days -6, -5, -4, -3)</description>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Priming regimen: 2000 mg/m^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).</description>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituxan (rituximab)</intervention_name>
    <description>Priming regimen: 375 mg/m^2 intravenous day 1, 4. Conditioning and transplant regimen: 750 mg/m^2 intravenous infusion, day -7.</description>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
    <other_name>Rituximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Priming regimen: 10 micrograms/kg/day subcutaneous, starting day 6. Conditioning and transplant regimen: 5 micrograms/kg/day subcutaneous, day +1 until ANC &gt;500 microliters.</description>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
    <other_name>GCSF (growth colony stimulating factor)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Priming regimen:1000 mg intravenous over 30 minutes, day 1.</description>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
    <other_name>Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <description>Lymphoablative regimen using cyclophosphamide, rituximab, and fludarabine followed by a CD34 cell selected autologous stem cell transplant.</description>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Standard human immunology research laboratory ex vivo studies.</description>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.</description>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Conditioning and transplant regimen 25-50 mg orally or intravenously.</description>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Priming regimen: 600 mg/m^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.</description>
    <arm_group_label>Autologous HSCT in SLE</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -INCLUSION CRITERIA

          1. Age 15-40 years

          2. Must fulfill at least 4 of the following 11 criteria for systemic lupus erythematous
             (SLE) as defined by the American College of Rheumatology:

             -Malar rash. Fixed erythema, flat or raised, over the malar eminences, tending to
             spare the nasolabial folds.

               -  Discoid rash. Erythematous raised patches with adherent keratotic scaling and
                  follicular plugging; atrophic scarring may occur in older lesions.

               -  Photosensitivity. Skin rash as a result of unusual reaction to sunlight, by
                  patient history or physician observation.

               -  Oral ulcers. Oral or nasopharyngeal ulcerations, usually painless, observed by a
                  physician.

               -  Arthritis. Nonerosive arthritis involving two or more peripheral joints,
                  characterized by tenderness, swelling, or effusion.

               -  Serositis. a.) Pleuritis - convincing history of pleuritic pain or rub heard by a
                  physician or evidence of pleural effusion

             OR

             b.) Pericarditis - documented by electrocardiogram (ECG) or rub or evidence of
             pericardial effusion

             -Renal disorder. a.) Persistent proteinuria greater than 0.5 grams per day or greater
             than 3+ if quantitation not performed

             OR

             b.) Cellular casts - may be red cell, hemoglobin, granular, tubular, or mixed.

               -  Neurologic disorder. a.) Seizures - in the absence of offending drugs or known
                  metabolic derangements; eg, uremia, ketoacidosis, or electrolyte imbalance

             OR

             b.) Psychosis - in the absence of offending drugs or known metabolic derangements; eg,
             uremia, ketoacidosis, or electrolyte imbalance

             -Hematologic disorder. a.) Hemolytic anemia - with reticulocytosis

             OR

             b.) Leukopenia - less than 4000/ L total on two or more occasions

             OR

             c.) Lymphopenia - less than 1500/ L on two or more occasions

             OR

             d.) Thrombocytopenia - less than 100,000/ L in the absence of offending drugs

               -  Immunologic disorder. a.) Anti-deoxyribonucleic acid (DNA): antibody to native
                  DNA in abnormal titer

             OR

             b.) Anti-SM: presence of antibody to SM nuclear antigen

             OR

             c.) Positive finding of antiphospholipid antibodies based on (1) an abnormal serum
             level of immunoglobulin G (IgG) or immunoglobulin M (IgM) anti-cardiolipin antibodies,
             (2) a positive test result for lupus anticoagulant using a standard method, or (3)
             false positive serologic test for syphilis known to be positive for at least 6 months
             and confirmed by Treponema Pallidum immobilization or fluorescent treponemal antibody
             absorption test

             -Antinuclear antibodies. An abnormal titer of ANAs by immunofluorescence or an
             equivalent assay at any point in time in the absence of drugs known to be associated
             with drug-induced lupus syndrome.

          3. Have severe and active lupus, refractory to immunosuppressive therapy, defined as one
             of the following (a-d):

             a.Nephritis: Biopsy proven Diffuse Proliferative Glomerulonephritis (World Health
             Organization (WHO) Class IV) with or without superimposed membranous changes

             i.Active disease:

          1. A kidney biopsy within three months of enrollment showing active WHO Class IV disease.
             Activity will be determined based on the presence of endocapillary cellular
             proliferation compromising the capillary loops or cellular crescents or necrosis on
             light microscopy or subendothelial deposits on electron microscopy.

          2. If a biopsy is contraindicated patients can be enrolled if they had a previous biopsy
             showing Diffuse Proliferative Glomerulonephritis (WHO Class IV) and at the time of
             enrollment have all of the following:

               1. Proteinuria greater than 1gm/day

               2. Active urine sediment defined as hematuria (greater than 10 red blood cell
                  (RBC)/hpf (high power field) on a nephrology urinalysis of a 50 mL urine sample)
                  with dysmorphic RBC and/or cellular casts on a nephrology urinalysis of a 50 mL
                  urine sample

               3. Low C3 (less than 69 mg/dL) and/or elevated dsDNA antibodies (greater than 25EU)

          3. Need for prednisone greater than 20 mg/day due to increased renal activity after at
             least 6 months of cyclophosphamide.

        ii. Treatment resistant:

          1. Patients with active disease after at least 6 months of intravenous pulse
             cyclophosphamide +/- iv methylprednisolone and daily oral prednisone, or

          2. Early flare: those who have reactivation of their nephritis during or within 6 months
             of completing cyclophosphamide therapy

          3. Recalcitrant disease: two or more recurrences of lupus nephritis within five years of
             enrollment. All flares must have received adequate therapy and least one of the
             episodes must have been treated with minimum 6 months of intravenous pulse
             cyclophosphamide plus iv methylprednisolone and maintenance oral prednisone.

             Central nervous system (CNS) lupus: Lupus CNS manifestations indicative of
             encephalitis or myelitis or vasculitis. Concomitant CNS diseases should be excluded.
             (e.g. infections, multiple sclerosis; patients fulfilling multiple sclerosis (MS) and
             SLE criteria will be excluded). Clinical signs and symptoms must be supported by
             objective findings of CNS inflammation.

             i. Active disease:

             Signs/symptoms that are accepted for disease activity:

             -Clinical signs and symptoms compatible with focal CNS damage -Severe global
             neurocognitive/psychiatric impairment (eg: psychosis, organic brain syndrome, severe
             depression)

             -Intractable seizures

             Clinical findings must be supported by at least one of the following:

               1. Magnetic resonance imaging (MRI) findings consistent with transverse myelitis or

                  Central nervous system (CNS) vasculitis

                  - Signs of inflammation on MRI are either the presence of Gadolinium
                  (Gd)-enhancing lesions, or the increase of the number and/or volume of
                  T2-weighted lesions (or lesions showing up on fluid attenuated inversion recovery
                  (FLAIR) imaging). We will use the standard MS protocol sequences, which are
                  routinely used in the Clinical Center to evaluate inflammatory CNS lesions.

               2. If patient has seizures/psychiatric signs and symptoms in the absence of clear
                  signs of vasculitis or cerebritis by MRI, the cerebral spinal fluid (CSF) should
                  show protein elevation above normal levels and abnormal number of white blood
                  cells (WBCs) or intrathecal IgG synthesis/or oligoclonal bands.

               3. Need for prednisone greater than 20 mg/day due to increased CNS activity (see
                  above) after at least three months of cyclophosphamide therapy.

             ii-Treatment resistant:

             a) Active disease after a minimum of three months of oral or intravenous
             cyclophosphamide, or

             b) Early flare: reactivation of CNS lupus within 6 months of completing
             cyclophosphamide therapy

             c. Recalcitrant disease: two or more recurrences of CNS lupus within five years of
             enrollment. All flares must have received adequate therapy and at least one of the
             episodes must have been treated with minimum three months of oral or intravenous
             cyclophosphamide.

             Pulmonary lupus

             i. Active disease:

               1. Lung biopsy showing active pneumonitis, alveolitis or pulmonary vasculitis after
                  the minimally required therapy within one month of enrollment or

               2. If a biopsy is contraindicated within one month of enrollment, patients may be
                  included if they had a biopsy at the start or during cyclophosphamide treatment
                  showing active pneumonitis, alveolitis or pulmonary vasculitis (as above) and
                  have abnormal or worsening pulmonary function tests with a chest computed
                  tomography (CT) consistent with active pneumonitis, alveolitis or vasculitis
                  within 2 weeks of enrollment and at the time of enrollment have a CT consistent
                  with active disease.

               3. Need for prednisone greater than 20 mg/day due to increased pulmonary lupus
                  activity after minimum of three months of cyclophosphamide.

                  ii. Treatment resistant:

               4. Ongoing or recurrent active pulmonary lupus after a minimum of three months of
                  oral or intravenous cyclophosphamide, or

               5. Early flare: reactivation of pulmonary lupus (as defined above) within 6 months
                  of completing cyclophosphamide therapy.

               6. Recalcitrant disease: two or more recurrences of pulmonary as described above
                  within five years of enrollment. All flares must have received adequate therapy
                  and at least one of the episodes must have been treated with minimum 3 months of
                  oral or intravenous cyclophosphamide.

             i) Active disease:

             a) Severe immune-mediated thrombocytopenia (platelet count less than 20,000/mm^3 or
             less than 50,000/mm^3 with history of bleeding), or

             b) Severe immune-mediated anemia (requiring transfusions to maintain hemoglobin (Hb)
             greater than 8.0 g/dL or to treat symptoms of anemia) c) Need for prednisone greater
             than 20 mg/day due to increased hematologic lupus activity after therapy as described
             in section ii.a).

             ii) Treatment resistant:

             a) Active disease as defined above after a minimum of three months of high dose oral
             or pulse corticosteroids +/- intravenous immunoglobulin (IVIg) (or WinRho) and
             splenectomy, or

             b) Early flare: reactivation of hematologic lupus (as defined above) within 6 months
             of completing above therapy.

             c) Recalcitrant disease: two or more recurrences of immune-mediated thrombocytopenia
             or anemia, as described above, within five years of enrollment. All flares must have
             received adequate therapy and at least one of the episodes must have been treated by
             splenectomy.

             EXCLUSION CRITERIA

        1. Inability to provide written informed consent prior to entry in the protocol

        2. Pregnant or lactating women. Women of childbearing potential are required to have a
        negative pregnancy test at screening

        3. Women of childbearing potential who are not practicing or who are unwilling to practice
        birth control during the entire study

        4. Men who are unwilling to practice birth control for the first 6 months after the
        transplant

        5. Evidence of infection with hepatitis B, hepatitis C, or human immunodeficiency virus
        (HIV)

        6. History of malignancy other than basal cell carcinoma of the skin

        7. Carbon monoxide diffusing capacity (DLCO) corrected less than 45%

        8. Left ventricular ejection fraction (LVEF) less than 45%, determined by ECHO cardiogram
        or MUGA

        9. Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase
        (SGPT) greater than 2x upper limit of normal (unless active myopathy is proven by elevation
        of serum aldolase levels and the patient has no obvious hepatic disease) and/or bilirubin
        greater than 2.0 (unless due to isolated hemolysis).

        10. Calculated glomerular filtration rate less than 30 ml/min using the modification of
        diet in renal disease (MDRD) equation estimate:

        Glomerular filtration rate (GFR) (ml/min/173 m^2) =186.3 x (Pcr) exponential -1.154 x (age)
        exponential -0.203 x 1.212 (if black) x 0.742 (if female)

        11. Late flare (patients who have target organ flare, that is not within the time frame
        defined as early flare, will not be considered as treatment failures until they receive the
        minimally required therapy for this flare episode and fail to respond to it)

        12. Abnormal bone marrow cytogenetics

        13. Significant concurrent medical condition or any significant circumstance that could
        affect the patient's ability to tolerate or complete the study

        14. Live vaccines within 4 weeks of starting the priming regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Pavletic, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001 Nov;1(2):147-53. Review.</citation>
    <PMID>11905822</PMID>
  </reference>
  <reference>
    <citation>Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.</citation>
    <PMID>9048514</PMID>
  </reference>
  <reference>
    <citation>Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001 Sep;2(9):764-6.</citation>
    <PMID>11526379</PMID>
  </reference>
  <results_reference>
    <citation>Illei GG, Cervera R, Burt RK, Doria A, Hiepe F, Jayne D, Pavletic S, Martin T, Marmont A, Saccardi R, Voskuyl AE, Farge D. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis. 2011 Dec;70(12):2071-4. doi: 10.1136/ard.2010.148049. Epub 2011 Aug 26.</citation>
    <PMID>21873334</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2004</study_first_submitted>
  <study_first_submitted_qc>February 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2004</study_first_posted>
  <results_first_submitted>March 25, 2014</results_first_submitted>
  <results_first_submitted_qc>May 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2014</results_first_posted>
  <last_update_submitted>April 9, 2017</last_update_submitted>
  <last_update_submitted_qc>April 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Steven Pavletic, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Refractory SLE</keyword>
  <keyword>Immunoablation</keyword>
  <keyword>Immunological Recovery</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Mechanism of Disease</keyword>
  <keyword>Lupus</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>SLE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Mesna</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Autologous HSCT in SLE</title>
          <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, and diphenhydramine. Stem cell transplant infusion day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal per PI, PI put study on hold</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous HSCT in SLE</title>
          <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.85" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relapse-free Complete Clinical Response</title>
        <description>Complete clinical response is defined as complete clinical response in the target organ and no clinical signs of active lupus as determined by a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of ≤3; prednisone ≤10mg/day at 6 months and ≤5mg/day at 12 months or later.</description>
        <time_frame>60 months</time_frame>
        <population>Ninth participant was taken off study before proceeding with transplant per principal investigator due to decision to put study on hold.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, and diphenhydramine. Stem cell transplant infusion day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse-free Complete Clinical Response</title>
          <description>Complete clinical response is defined as complete clinical response in the target organ and no clinical signs of active lupus as determined by a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of ≤3; prednisone ≤10mg/day at 6 months and ≤5mg/day at 12 months or later.</description>
          <population>Ninth participant was taken off study before proceeding with transplant per principal investigator due to decision to put study on hold.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="36" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, and diphenhydramine. Stem cell transplant infusion day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Nuclear Antibody</title>
        <description>Anti-Nuclear antibody is a well accepted biological clinical laboratory marker of systemic lupus. Range of normal values is 0-0.9 EU.</description>
        <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Nuclear Antibody</title>
          <description>Anti-Nuclear antibody is a well accepted biological clinical laboratory marker of systemic lupus. Range of normal values is 0-0.9 EU.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>EU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years 9 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extractable Nuclear Antigen (ENA)</title>
        <description>Extractable nuclear antigen is a well accepted biological clinical laboratory marker of systemic lupus. Range of normal values is 0-19.</description>
        <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Extractable Nuclear Antigen (ENA)</title>
          <description>Extractable nuclear antigen is a well accepted biological clinical laboratory marker of systemic lupus. Range of normal values is 0-19.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>EU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" spread="74.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" spread="70.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="73.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="67.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" spread="57.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2" spread="58.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6" spread="60.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" spread="49.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="41.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Double Stranded Deoxyribonucleic Acid (DNA) Antibody</title>
        <description>Anti-Double stranded deoxyribonucleic acid antibody is a well accepted biological clinical laboratory marker especially specific for systemic lupus. Range of normal values is 0-24 IU.</description>
        <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Double Stranded Deoxyribonucleic Acid (DNA) Antibody</title>
          <description>Anti-Double stranded deoxyribonucleic acid antibody is a well accepted biological clinical laboratory marker especially specific for systemic lupus. Range of normal values is 0-24 IU.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="24.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Smith-Ribonuclear Protein Antibody</title>
        <description>Anti-Smith-Ribonuclear protein antibody is a well accepted biological clinical laboratory marker of systemic lupus.Range of normal values is 0-19 EU.</description>
        <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months and 2 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Smith-Ribonuclear Protein Antibody</title>
          <description>Anti-Smith-Ribonuclear protein antibody is a well accepted biological clinical laboratory marker of systemic lupus.Range of normal values is 0-19 EU.</description>
          <units>EU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" spread="49.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6" spread="53.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="40.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" spread="41.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="40.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="34.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="28.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.67" spread="44.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>White Blood Cells</title>
        <description>The white blood cell test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 3.4-9.6 K/uL.</description>
        <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>White Blood Cells</title>
          <description>The white blood cell test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 3.4-9.6 K/uL.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>K/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.89" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.32" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.81" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.17" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.34" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Neutrophil Count</title>
        <description>The absolute neutrophil count test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 1.29-7.5 K/uL.</description>
        <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Neutrophil Count</title>
          <description>The absolute neutrophil count test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 1.29-7.5 K/uL.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>K/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.11" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.78" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Lymphocyte Count</title>
        <description>The absolute lymphocyte count test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 0.45-4.9 K/uL.</description>
        <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Lymphocyte Count</title>
          <description>The absolute lymphocyte count test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 0.45-4.9 K/uL.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>K/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0065" spread="0.0064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Count</title>
        <description>The platelet count test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 162-380 K/uL.</description>
        <time_frame>Day -7, day 0, 1 3, and 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Count</title>
          <description>The platelet count test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 162-380 K/uL.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>K/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251" spread="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" spread="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187" spread="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226" spread="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210" spread="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308" spread="251.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272" spread="125.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cluster of Differentiation 3 (CD3) + Cells</title>
        <description>The CD3+Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 650-2108 uL.</description>
        <time_frame>Day 0, 1 month, 3 months, 6 months, 1 year and 2 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Cluster of Differentiation 3 (CD3) + Cells</title>
          <description>The CD3+Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 650-2108 uL.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>cells/mL^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.47" spread="210.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="435.97" spread="335.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="699.47" spread="256.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1493.29" spread="605.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1678.76" spread="888.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cluster of Differentiation 4 (CD4) + Cells</title>
        <description>The CD4 + Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 358-1259 uL.</description>
        <time_frame>Day 0, 1 month, 3 months, 6 months, 1 year and 2 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Cluster of Differentiation 4 (CD4) + Cells</title>
          <description>The CD4 + Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 358-1259 uL.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>cells/mL^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.37" spread="117.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.8" spread="101.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.25" spread="193.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="702.87" spread="362.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="958.03" spread="735.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cluster of Differentiation 8 (CD8) + Cells</title>
        <description>The CD8 + Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 194-836 u/L.</description>
        <time_frame>Day 0, 1 month, 3 months, 6 months, 1 year and 2 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Cluster of Differentiation 8 (CD8) + Cells</title>
          <description>The CD8 + Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 194-836 u/L.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>cells/mL^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.68" spread="112.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318.47" spread="259.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.91" spread="139.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="736.67" spread="532.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="674.69" spread="378.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cluster of Differentiation 19 (CD19) + Cells</title>
        <description>The CD19 + Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 47-409 u/L.</description>
        <time_frame>Day 0, 1 month, 3 months, 6 months, 1 year and 2 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Cluster of Differentiation 19 (CD19) + Cells</title>
          <description>The CD19 + Cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 47-409 u/L.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>cells/mL^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="17.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.32" spread="58.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.69" spread="116.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.83" spread="316.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Natural Killer Cells</title>
        <description>The natural killer cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 87-505 uL.</description>
        <time_frame>Day 0, 1 month, 3 months, 6 months, 1 year and 2 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Natural Killer Cells</title>
          <description>The natural killer cells test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Range of normal values is 87-505 uL.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>cells/mL^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.06" spread="81.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.57" spread="93.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.18" spread="63.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.9" spread="136.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.18" spread="68.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)</title>
        <description>The SLEDAI activity index test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Complete clinical response is defined as complete clinical response in the target organ and no clinical signs of active lupus as determined by a SLEDAI score of ≤3; partial response is at least 50% improvement in general disease activity as measured by SLEDAI. Remission is a SLEDAI score &lt;3 and prednisone &lt;10mg/day. 6+ indicates active disease requiring therapy. A score of 0 indicates a better outcome and a score greater then 6+ indicates a worse outcome.</description>
        <time_frame>Day -7, day 0, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years and 3 years.</time_frame>
        <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HSCT in SLE</title>
            <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)</title>
          <description>The SLEDAI activity index test was performed to investigate immunological efficacy and mechanisms of response after lymphodepleting auto-hematopoietic stem cell transplant for systemic lupus erythematosus. Complete clinical response is defined as complete clinical response in the target organ and no clinical signs of active lupus as determined by a SLEDAI score of ≤3; partial response is at least 50% improvement in general disease activity as measured by SLEDAI. Remission is a SLEDAI score &lt;3 and prednisone &lt;10mg/day. 6+ indicates active disease requiring therapy. A score of 0 indicates a better outcome and a score greater then 6+ indicates a worse outcome.</description>
          <population>One participant was enrolled but the study was closed before the patient could be treated.</population>
          <units>scores on a scale.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Autologous HSCT in SLE</title>
          <description>Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>conduction abnormality/atrioventricular heart block: asystole</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal-Other (Specify)</sub_title>
                <description>laparoscopic surgery w/appendectomy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death Not Associated with CTCAE term: Death NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <description>(documented clinically or microbiologically) with grades 3 or 4 neutrophils (ANC &lt;1.0x10e9/L): lung (pneumonia)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>infection - Other (Specify, CMV antigenemia without neutropenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT/SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>AST/SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hydrocephalus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>neuropathy: motor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>neuropathy: sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - Other (Specify, __)</sub_title>
                <description>low HGB (anemia); low HGB</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bone marrow cellularity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="55" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="82" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="79" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="81" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="130" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <description>(e.g., thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS])</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other (Specify,bruising-skin)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia:: Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia:: Supraventricular arrhythmia NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia:: PVCs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia:: Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other (Specify, __)</sub_title>
                <description>2+L leg edema; 2+ pitting R leg edema; 3+ pitting L leg edema; 3+ pitting edema R leg; intermittent 2+, 3+ pitting b/l LE edema</description>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I (cTnI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear - Other (Specify, __)</sub_title>
                <description>hearing diminished on the left side</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain:: External ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid appearance (e.g., moon face, buffalo hump, centripetal obesity, cutaneous striae)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Masculinization of female</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - Other (Specify, __)</sub_title>
                <description>residual itching post herpetic area; episcleritis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vision-photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain:: Eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam):: Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain:: Abdomen NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other (Specify,decreased appetite )</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, __)</sub_title>
                <description>b/l flanks; intermittent pain in hips and knees</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection)(ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>(documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L):: Bladder (urinary)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>(documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L):: Urinary tract NOS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection - Other (Specify, __)</sub_title>
                <description>R toe infection, was believed fungal; clostridium difficile in stool</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Blood</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Bone (osteomyelitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Catheter-related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Conjunctiva</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Eye NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Pharynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Sinus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Small bowel NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Upper airway NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:: Urinary tract NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC:: Middle ear (otitis media)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC:: Urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="36" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="41" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="31" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="25" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="67" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesteremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="24" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="16" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="86" subjects_affected="7" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain:: Back</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain:: Bone</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain:: Chest wall</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain:: Chest/thorax NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain:: Muscle</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain:: Neck</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Extrapyramidal/involuntary movement/restlessness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mood alteration:: Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mood alteration:: Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mood alteration:: Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain:: Head/headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusion capacity (DL(co))</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Specify, __)</sub_title>
                <description>nasal congestion; nasal drainage</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of Grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify, scalp dermatitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Pavletic</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-402-4899</phone>
      <email>pavletis@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

